^
Association details:
Biomarker:NTRK1-KHDRBS1 fusion
Cancer:Sarcoma
Drug:Xalkori (crizotinib) (ALK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment

Published date:
04/30/2021
Excerpt:
...sarcoma carrying a neurotrophic tyrosine receptor kinase NTRK1-KHDRBS1 gene fusion that was diagnosed and treated at multiple hospitals...The patient achieved a long-term survival without tumor relapse after treatment with crizotinib.
DOI:
10.1186/s12957-021-02237-y